IntegraGen Partners with CRUK to Validate miRNA Marker for Colorectal Cancer Drug Response | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it is collaborating with Cancer Research UK to validate a microRNA as a biomarker for the prediction of progression-free survival in patients with metastatic colorectal cancer who have received anti-EGFR therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.